Stockscreener 앱 받기
1.36
5.43%
0.07
시간 외 거래:
1.32
-0.04
-2.94%
전일 마감가:
$1.29
열려 있는:
$1.3
하루 거래량:
102.67K
Relative Volume:
0.95
시가총액:
$35.36M
수익:
$2,000
순이익/손실:
$-9.12M
주가수익비율:
-3.4934
EPS:
-0.3893
순현금흐름:
$-3.35M
1주 성능:
+5.43%
1개월 성능:
+24.77%
6개월 성능:
-33.00%
1년 성능:
-32.00%
1일 변동 폭
$1.30
$1.4327
1주일 범위
$1.19
$1.4327
52주 변동 폭
$0.8801
$5.48
Abvc Biopharma Inc Stock (ABVC) Company Profile
명칭
Abvc Biopharma Inc
전화
510-668-0881
주소
44370 OLD WARM SPRINGS BLVD., FREMONT
Compare ABVC vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABVC
Abvc Biopharma Inc
|
1.36 | 32.76M | 2,000 | -9.12M | -3.35M | -0.3893 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Abvc Biopharma Inc 주식(ABVC)의 최신 뉴스
ABVC BioPharma Inc. (ABVC) Surges 7.39% — Testing Key Resistance at $1.34Relative Volume - newsline.com
ABVC Q1 2025 Earnings: Net Loss of -$0.06 Per Share Reflects Pre‑Revenue Development Stage; Stock Declines 9.2% - newsline.com
ABVC BioPharma Inc. (ABVC) Edges Higher as Shares Test Resistance Near $1.41Ichimoku Kumo Break - newsline.com
ABVC BioPharma Inc. (ABVC) Q1 2025 Earnings: Narrowing Losses Amid Clinical ProgressRevenue Recognition Risk - newsline.com
ABVC BioPharma Slips 7.6%: Support at $1.26 in Focus After Volatile SessionSeasonality Effect - newsline.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
ABVC BioPharma Surges 6.64%: Shares Break Above Key Support as Momentum BuildsUp Down Volume - newsline.com
ABVC PE Ratio & Valuation, Is ABVC Overvalued - Intellectia AI
ABVC Q1 2025 Earnings: Pre‑Revenue Biotech Reports Net Loss as Pipeline Development Continues - newsline.com
ABVC BioPharma Inc. (ABVC) Q1 2025 Earnings: Modest Loss Reported Amid Ongoing Clinical Development - The Legal Advocate
ABVC BioPharma Creeps Higher, Testing Resistance at $1.48Bullish Percent Index - The Legal Advocate
ABVC BioPharma Consolidates at $1.39 as Support and Resistance Levels NarrowPCR Divergence - The Legal Advocate
ABVC BioPharma Surges 13%: Key Levels and Potential ScenariosShort Term Trading Ideas - thelegaladvocate.com
ABVC BioPharma Inc. (ABVC) Surges 9.65% in Active Trading as Biotech Investor Sentiment ImprovesMcClellan Summation - The Legal Advocate
ABVC BioPharma Inc. (ABVC) Edges Higher After Recent Pullback, Testing Key Resistance LevelIV Expansion Alert - Newser
ABVC BioPharma Inc. Q1 2025 Earnings: Narrowed Loss Highlights Continued Pipeline ProgressBuyback Announcement Report - The Legal Advocate
ABVC BioPharma Inc. (ABVC) Holds Steady Above Support After Modest GainSocial Flow Trades - Newser
ABVC BioPharma Reports Continued Losses and No Revenue in Q1 2026, Raising Doubts About Financial Stability - Minichart
Why Is ABVC BioPharma, Inc. (ABVC) Stock Up Today? - Meyka
Why Is ABVC BioPharma, Inc. (ABVC) Stock Down Today? - Meyka
ABVC BioPharma, Inc. 1Q 2026: Revenue ($1.55M), Net income ($1.56M), EPS ($0.06) — 10-Q Summary - TradingView
ABVC: Q1 2026 saw a $1.69M net loss, no revenue, and a $4.74M working capital deficit - TradingView
ABVC BioPharma (NASDAQ: ABVC) posts Q1 loss and going concern warning - Stock Titan
ABVC BioPharma Delays Quarterly SEC Filing - TipRanks
ABVC (ABVC) files Form 12b-25: late 10-Q for March 31, 2026 - Stock Titan
TradingKey - TradingKey
How sustainable is BioPharma (ABVC) profit margins? (Institutional Selling) 2026-05-08MACD Signals - newser.com
ABVC BioPharma drops 6.14% after Q1 2025 quarterly earnings post a 0.06 dollar per share loss with no prior analyst estimates.Management Guidance Update - newsline.com
ABVC BioPharma Inc. posts $0.06 EPS loss, no published estimatesGuidance Accuracy Score - newsline.com
BioPharma (ABVC) Stock: Why Industry Position (Pulls Back) 2026-04-15Breakout Signals - Cổng thông tin điện tử tỉnh Lào Cai
ABVC Options Volatility — NASDAQ:ABVC - TradingView
ABVC Options Chain — NASDAQ:ABVC - TradingView
Published on: 2026-04-10 10:41:09 - baoquankhu1.vn
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Is BioPharma (ABVC) Stock Growing Now | Price at $1.33, Up 20.91%Fibonacci Retracement - newsline.com
ABVC Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
ABVC BioPharma Shareholders Back Board, Equity Plan Changes - TipRanks
ABVC BioPharma shareholders approve director slate and equity plan at annual meeting By Investing.com - Investing.com South Africa
ABVC BioPharma shareholders approve director slate and equity plan at annual meeting - Investing.com
ABVC BioPharma (ABVC) investors re-elect board and approve 2026 plan - stocktitan.net
ABVC BioPharma | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filingmoomoo - Moomoo
Aug Weekly: What is ABVC BioPharma Incs market positionEarnings Summary Report & Precise Buy Zone Identification - baoquankhu1.vn
Bull Run: Is ABVC BioPharma Inc part of any major indexWeekly Stock Analysis & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Aug Breakouts: Can ABVC BioPharma Inc benefit from deglobalizationTrade Analysis Report & Precise Swing Trade Entry Alerts - baoquankhu1.vn
ABVC BioPharma (ABVC) plans 2026 virtual meeting, director votes and equity plan increase - Stock Titan
ABVC SEC FilingsAbvc Biopharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ABVC BioPharma Reports 179% Asset Growth in 2025, Shifts Toward Hybrid Business Model - citybuzz -
According to the latest filing submitted to the U.S. Securities and Exchange Commission (SEC), ABVC BioPharma, Inc. has identified significant deficiencies in its internal control over financial reporting for the fiscal year 2025. - Bitget
ABVC BioPharma Reports 2025 Form 10-K - Yahoo Finance
ABVC BioPharmaquarterly period ended September, 2025 financial statements should not be relied upon - marketscreener.com
Abvc Biopharma Inc (ABVC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):